A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

Not specified

Study Completion Date

June 30, 2000

Conditions
HIV Infections
Interventions
DRUG

Ritonavir

DRUG

Nelfinavir mesylate

DRUG

Saquinavir

DRUG

Nevirapine

DRUG

Lamivudine

DRUG

Stavudine

DRUG

Didanosine

Trial Locations (19)

10016

Bellevue Hosp / New York Univ Med Ctr, New York

10032

Columbia Presbyterian Med Ctr, New York

Incarnation Children's Ctr / Columbia Presbyterian Med Ctr, New York

11021

North Shore Univ Hosp, Great Neck

13210

SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse

23219

Med College of Virginia, Richmond

32503

Sacred Heart Children's Hosp / CMS of Florida, Pensacola

33161

Univ of Miami (Pediatric), Miami

35233

Univ of Alabama at Birmingham - Pediatric, Birmingham

39213

Univ of Mississippi Med Ctr, Jackson

60612

Cook County Hosp, Chicago

212874933

Johns Hopkins Hosp - Pediatric, Baltimore

381052794

Saint Jude Children's Research Hosp of Memphis, Memphis

606143394

Chicago Children's Memorial Hosp, Chicago

701122699

Tulane Univ / Charity Hosp of New Orleans, New Orleans

900951752

UCLA Med Ctr / Pediatric, Los Angeles

021155724

Children's Hosp of Boston, Boston

016550001

Univ of Massachusetts Med School, Worcester

071032714

Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001108 - A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses | Biotech Hunter | Biotech Hunter